PMID- 23994800
OWN - NLM
STAT- MEDLINE
DCOM- 20140402
LR  - 20191112
IS  - 1349-7413 (Electronic)
IS  - 0911-4300 (Linking)
VI  - 36
IP  - 4
DP  - 2013
TI  - Efficacy of high-dose intravenous immunoglobulin therapy for peripheral 
      neuropathy in the remission stage of eosinophilic granulomatosis with 
      polyangiitis (EGPA, Churg-Strauss syndrome).
PG  - 217-25
AB  - BACKGROUND: Most patients with eosinophilic granulomatosis with polyangiitis 
      (EGPA ; Churg-Strauss syndrome) suffer from peripheral neuropathy. The neuropathy 
      affects ADLs in not only the active stage, but also the remission stage of EGPA. 
      Recently, high-dose intravenous immunoglobulin therapy (IVIg) is known to be 
      effective for peripheral neuropathy in the active stage of EGPA. However, the 
      effect of IVIG for peripheral neuropathy in the remission stage remains obscure. 
      OBJECTIVE: This study assessed the efficacy of high-dose IVIg for peripheral 
      neuropathy in the remission stage of EGPA. PATIENTS & METHODS: Six patients with 
      peripheral neuropathy (duration : 3 months~7 years) in the remission stage of 
      EGPA were investigated. IVIg was performed with an immunoglobulin dose of 400 
      mg/kg daily (intravenous drip) for 5 days. Neuropathy was evaluated with the 
      manual muscle strength test (MMT) and the visual analogue scale (VAS). RESULTS: 
      MMT improved in 4 of 7 patients (57.1%). MMT score increased 10.0+/-7.2 after IVIG. 
      VAS (Numbness and neuralgia) improved in 6 of 7 patients (85.7%). Average VAS 
      improved in the range of 46 mm to 61 mm. Side effect was detected in one patient 
      (headache) only even though all patients underwent this therapy. CONCLUSION: 
      These results suggested that IVIg therapy was safe and effective in patients with 
      persistent peripheral neuropathy even in the remission stage of EGPA.
FAU - Matsuda, Tomoko
AU  - Matsuda T
AD  - First Department of Internal Medicine (Rheumatology and Nephrology), Kyorin 
      University School of Medicine.
FAU - Arimura, Yoshihiro
AU  - Arimura Y
FAU - Yoshihara, Ken
AU  - Yoshihara K
FAU - Komagata, Yoshinori
AU  - Komagata Y
FAU - Kaname, Shinya
AU  - Kaname S
FAU - Yamada, Akira
AU  - Yamada A
LA  - eng
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho Meneki Gakkai Kaishi
JT  - Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology
JID - 9505992
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Aged
MH  - Churg-Strauss Syndrome/*therapy
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Peripheral Nervous System Diseases/*drug therapy
MH  - Remission Induction
MH  - Treatment Outcome
EDAT- 2013/09/03 06:00
MHDA- 2014/04/03 06:00
CRDT- 2013/09/03 06:00
PHST- 2013/09/03 06:00 [entrez]
PHST- 2013/09/03 06:00 [pubmed]
PHST- 2014/04/03 06:00 [medline]
AID - DN/JST.JSTAGE/jsci/36.217 [pii]
AID - 10.2177/jsci.36.217 [doi]
PST - ppublish
SO  - Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(4):217-25. doi: 10.2177/jsci.36.217.